Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Alnylam Pharmace. buy klostergang

Start price
€71.64
01.10.19 / 50%
Target price
€150.00
04.11.21
Performance (%)
96.54%
End price
€140.80
17.06.21
Summary
This prediction ended on 17.06.21 with a price of €140.80. With a performance of 96.54% the BUY prediction by klostergang was a big success. klostergang has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Performance without dividends (%)
Name 1w 1m 1y 3y
Alnylam Pharmace. 5.318% 5.318% -19.198% 23.399%
iShares Core DAX® 2.149% 5.415% 21.385% 22.595%
iShares Nasdaq 100 0.838% 1.926% 44.386% 55.330%
iShares Nikkei 225® 1.143% 2.887% 27.641% 9.481%
iShares S&P 500 1.265% 3.698% 33.327% 49.646%

Comments by klostergang for this prediction

In the thread Alnylam Pharmace. diskutieren
Prediction Buy
Perf. (%) 96.54%
Target price 130.000
Change
Ends at 04.11.21

Buy mit Kursziel 130,0

Prediction Buy
Perf. (%) 96.54%
Target price 140.000
Change
Ends at 04.11.21

Kursziel geändert auf 140,0

Prediction Buy
Perf. (%) 96.54%
Target price 150.000
Change
Ends at 04.11.21

Kursziel geändert auf 150,0